docetaxel anhydrous has been researched along with ribociclib in 2 studies
| Studies (docetaxel anhydrous) | Trials (docetaxel anhydrous) | Recent Studies (post-2010) (docetaxel anhydrous) | Studies (ribociclib) | Trials (ribociclib) | Recent Studies (post-2010) (ribociclib) |
|---|---|---|---|---|---|
| 12,110 | 3,216 | 6,920 | 330 | 56 | 322 |
| Protein | Taxonomy | docetaxel anhydrous (IC50) | ribociclib (IC50) |
|---|---|---|---|
| Cyclin-T1 | Homo sapiens (human) | 1.1228 | |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | 0.0156 | |
| G1/S-specific cyclin-D1 | Homo sapiens (human) | 0.0235 | |
| G1/S-specific cyclin-D3 | Homo sapiens (human) | 0.0352 | |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | 1.1228 | |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | 0.0393 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afratis, K; Gavras, H; Karamanos, NK; Koutsakis, C; Leonardi, S; Papaioannou, D; Piperigkou, Z; Rassias, G; Rigopoulou, D; Vachlioti, E | 1 |
| Aggarwal, R; Carneiro, BA; de Kouchkovsky, I; Fong, L; Friedlander, T; Lewis, C; Paris, PL; Phone, A; Rao, A; Ryan, CJ; Small, EJ; Szmulewitz, RZ; Zhang, L | 1 |
1 trial(s) available for docetaxel anhydrous and ribociclib
| Article | Year |
|---|---|
A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer.
Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Cyclin-Dependent Kinase 4; Docetaxel; Febrile Neutropenia; Humans; Male; Prednisone; Prostatic Neoplasms, Castration-Resistant; Purines; Treatment Outcome | 2022 |
1 other study(ies) available for docetaxel anhydrous and ribociclib
| Article | Year |
|---|---|
Potent antiproliferative activity of bradykinin B2 receptor selective agonist FR-190997 and analogue structures thereof: A paradox resolved?
Topics: Anti-Bacterial Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MCF-7 Cells; Quinolines; Receptor, Bradykinin B2 | 2021 |